A314130 Stock Overview
Genome & Company, a clinical stage biotechnology company, researches and develops novel-targeted immuno-oncology therapeutics in the field of immuno-oncology, skin diseases, and autism in South Korea.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Genome & Company Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩7,030.00 |
| 52 Week High | ₩25,300.00 |
| 52 Week Low | ₩6,800.00 |
| Beta | 0.97 |
| 1 Month Change | -27.60% |
| 3 Month Change | -33.74% |
| 1 Year Change | -67.38% |
| 3 Year Change | -86.13% |
| 5 Year Change | -82.85% |
| Change since IPO | -24.65% |
Recent News & Updates
Positive Sentiment Still Eludes Genome & Company (KOSDAQ:314130) Following 25% Share Price Slump
Apr 11
Is Genome (KOSDAQ:314130) Using Debt In A Risky Way?
Mar 08Shareholder Returns
| A314130 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | -5.0% | -4.0% | -3.3% |
| 1Y | -67.4% | 0.7% | 1.2% |
Return vs Industry: A314130 underperformed the KR Biotechs industry which returned 0.7% over the past year.
Return vs Market: A314130 underperformed the KR Market which returned 1.2% over the past year.
Price Volatility
| A314130 volatility | |
|---|---|
| A314130 Average Weekly Movement | 6.7% |
| Biotechs Industry Average Movement | 8.2% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in KR Market | 11.9% |
| 10% least volatile stocks in KR Market | 2.4% |
Stable Share Price: A314130's share price has been volatile over the past 3 months.
Volatility Over Time: A314130's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 105 | Jisoo Pae | genomecom.co.kr |
Genome & Company, a clinical stage biotechnology company, researches and develops novel-targeted immuno-oncology therapeutics in the field of immuno-oncology, skin diseases, and autism in South Korea. Its lead product candidate is GEN-001, an oral microbiome therapeutic candidate developed to have immune modulating activities. The company also develops GEN-501 targeting the non-responders of Dupilumab drugs with atopic skin diseases; and GENA-104 for the treatment of solid tumors, as well as microbiome-based products, including therapeutics, cosmeceuticals, and dietary supplements.
Genome & Company Fundamentals Summary
| A314130 fundamental statistics | |
|---|---|
| Market cap | ₩105.27b |
| Earnings (TTM) | -₩47.47b |
| Revenue (TTM) | ₩14.30b |
7.4x
P/S Ratio-2.2x
P/E RatioIs A314130 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A314130 income statement (TTM) | |
|---|---|
| Revenue | ₩14.30b |
| Cost of Revenue | ₩10.23b |
| Gross Profit | ₩4.06b |
| Other Expenses | ₩51.53b |
| Earnings | -₩47.47b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.17k |
| Gross Margin | 28.43% |
| Net Profit Margin | -332.02% |
| Debt/Equity Ratio | 19.1% |
How did A314130 perform over the long term?
See historical performance and comparison